Constantly Bombarded with New Drugs: What's a Cardiologist to Do?

Area of Science:

• Pharmacology
• Clinical Practice Guidelines
• Drug Therapeutics

Background:

• Physicians are inundated with direct-to-consumer and direct-to-physician drug advertising.
• Deciding which new drugs or indications to adopt presents a significant clinical challenge.

Purpose of the Study:

• To provide a practical framework for incorporating new medications into clinical practice.
• To illustrate this approach using empagliflozin, a widely marketed SGLT-2 inhibitor.

Main Methods:

• Review of clinical practice considerations for new drug integration.
• Case illustration using empagliflozin, an SGLT-2 inhibitor.

Main Results:

• Empagliflozin, an SGLT-2 inhibitor, is heavily marketed and included in guidelines.
• A commonsense approach is needed for evaluating and adopting new drugs.

Conclusions:

• A systematic approach aids physicians in incorporating new drugs like empagliflozin.
• Evidence-based guidelines and practical considerations are crucial for therapeutic decisions.